SEARCH:      Monitor Keywords |  Custom RSS

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

20130116403 - Fluorescent polymethine cyanine dyes: The invention encompasses fluorescent cyanine dyes and methods of using such dyes. In particular, the invention encompasses near infrared polymethine cyanine dyes.... Agent: The Washington University

20130116404 - Targeted non-invasive imaging probes of egfr expressing cells: A probe for imaging EGFR expressing cells includes an EGFR targeting moiety, a reporter moiety, and a hydrophilic linker that links the EGFR targeting moiety to the reporter moiety. The hydrophilic linker enhances solubility of the probe in an aqueous media as well as binding affinity of the probe to... Agent: Case Western Reserve University

20130116405 - Compositions comprising modified collagen and uses therefor: The invention provides modified collagen and related therapeutic and diagnostic methods.... Agent: The Johns Hopkins University

20130116406 - Borrelia antigens: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process... Agent: Intercell Ag

20130116407 - Controlled release from macromolecular conjugates: The invention relates to conjugates of macromolecular carriers and drugs comprising linkers that release the drug or a prodrug through rate-controlled beta-elimination, and methods of making and using the conjugates.... Agent:

20130116409 - Method for enriching methylated cpg sequences: Compositions and methods are provided for facilitating the enrichment of single-stranded DNA containing methylated CpG in a mixture containing methylated and unmethylated DNA. The compositions relate to methylation-binding protein domains that selectively bind to methylated single strand DNA. In embodiments of the invention, the methylated DNA is eluted in 0.4M-0.6M... Agent: New England Biolabs, Inc.

20130116408 - Virion derived protein nanoparticles for delivering radioisotopes for the diagnosis and treatment of malignant and systemic disease and the monitoring of therapy: The invention is directed to novel compositions and methods utilizing virion derived protein nanoparticles for delivery of medical imaging agents and therapeutic agents for the diagnosis and treatment of malignant and systemic diseases. The nanoparticles of the present invention are designed to deliver radioactive isotopes suitable for imaging a tumor... Agent: Aura Biosciences, Inc.

20130116410 - New stabilizing agent for pharmaceutical proteins: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.... Agent: Octaph Arma Ag

20130116411 - Methods of making hyaluronic acid/collagen compositions: Hyaluronic acid and collagen may be crosslinked in aqueous solution as described herein. The crosslinked macromolecular matrices obtained in this process may be used as a hydrogel for implants and fillers for human aesthetic and therapeutic products.... Agent: Allergan, Inc.

20130116412 - Production of post-translationally hydroxylated recombinant proteins in bacteria: Bacterial cells capable of producing recombinant proteins, such as post-translationally hydroxylated recombinant proteins, methods and kits for producing recombinant proteins, such as post-translationally hydroxylated recombinant proteins, and particular post-translationally hydroxylated recombinant collagen molecules produced by the methods and cells disclosed herein are provided by this invention.... Agent:

20130116413 - Purification of proteins: The invention describes a method for protein purification. More particularly, the invention relates to a purification process comprising protein A chromatography and anion exchange chromatography wherein protein A chromatography eluate is further purified by anion exchange chromatography at similar pH or at a pH less than or equal to 6.... Agent: Dr. Reddy's Laboratories Ltd.

20130116414 - Methods of extracting chemical compounds from organisms with resistant cell walls: A method is provided for extraction of chemical compounds from an organism having a cell wall that includes adding nanomaterials, which may be metallic nanofibers such as silver nanofibers, to the organism.... Agent: Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

20130109833 - Cyclic peptide compound or pharmacologically acceptable salt thereof and method for producing same: P

20130109834 - High salt-resistance antibacterial peptide and method for producing the same: The present invention is related to a high salt-resistance antibacterial peptide by increasing width of side chain of amino acids and/or increasing length of side chain of amino acids in the antibacterial peptide; and a method for increasing salt-resistance of antibacterial peptide by increasing width of side chain and/or increasing... Agent: National Tsing Hua University

20130109835 - Method for processing protein-containing materials to obtain mixtures of natural amino acids, low-molecular weight peptides and oligopeptides: A method for processing protein-containing materials and utilization of protein-containing waste for production of mixtures of natural amino acids, mixtures of low-molecular weight peptides, and mixtures of oligopeptides, which can be used in the manufacture of reagents for the detoxification and bactericidal treatment of sewage sludge, surfactants, wetting agents, foaming... Agent: P.m.k. Technological Treatment Ltd.

20130109837 - Methods of making a diagnostic composition and compositions therefrom: In one aspect, the invention provides a method for making a hydrophilic-silk composition. The method includes providing at least one strand of silk fiber, treating the silk fiber with an alkaline solution to provide at least one strand of degummed silk fiber, and treating the degummed silk fiber with a... Agent: Achira Labs Pvt. Ltd

20130109836 - Silk fibroin porous material and method for producing same: By a silk fibroin porous material containing silk fibroin and an amino acid and a method for producing a silk fibroin porous material including freezing a fibroin solution having an amino acid added to a fibroin aqueous solution and subsequently thawing the solution to obtain a porous material, a porous... Agent:

20130109838 - Method of altering the binding specificity of plasma proteins by oxidation-reduction: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood... Agent:

20130109842 - Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23: The present invention relates to amino acid sequences that are directed against the p19 subunit of IL-23; as well as protein, constructs and compounds comprising the same; and also nucleic acids encoding the same.... Agent: Ablynx N.v.

20130109840 - Anti-cmet antibody: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for... Agent: Pierre Fabre Medicament

20130109841 - Anti-cmet antibody: Antibody capable of binding specifically to the luman c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for... Agent: Pierre Fabre Medicament

20130109843 - Antibodies to human programmed death receptor pd-1: Antibodies which block binding of hPD-1 to hPD-L1 or hPD-L2 and their variable region sequences are disclosed. A method of increasing the activity (or reducing downmodulation) of an immune cell through the PD-1 pathway is also disclosed.... Agent: Mds Oss B.v.

20130109839 - Process for the modulation of the antagonistic activity of a monoclonal antibody: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target... Agent: Pierre Fabre Medicament

20130109844 - Anti-cmet antibody: Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for... Agent: Pierre Fabre Medicament

20130109845 - Fully human influenza m2 specific antibodies: The present invention relates to human antibodies, preferably to fully human antibodies, which are specifically binding to influenza M2e antigen. The invention further relates to individual light- and/or heavy chains of such antibodies, to nucleic acids encoding said antibodies or their light- and/or heavy chain, and to expression vectors for... Agent: Intercell Ag

20130109846 - Compositions monovalent for cd28 binding and methods of use: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially... Agent: Bristol-myers Squibb Company

20130109847 - Detection or quantification of desirable target molecules, novel dyes, composite dyes, and oligonucleotides or polynucleotides comprising such dyes: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides... Agent: Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.

20130102758 - Ezrin assay method for the in vitro diagnosis of colorectal cancer: A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence... Agent: Centre National De La Recherche Scientifique

20130102757 - Methods for selective targeting: A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to... Agent: Danisco US Inc.

20130102759 - Synthetic oligosaccharides for moraxella vaccine: The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by... Agent:

20130102760 - Immunoglobulin preparations having increased stability: The present invention relates to a protein preparation having increased stability, comprising a stabiliser selected from the group consisting of non-polar and basic amino acids and having a pH of 4.0 to 5.2. The invention further relates to a pharmaceutical composition and a method of stabilising protein preparations.... Agent: Csl Behring Ag

20130102761 - Solid phase for mixed-mode chromatographic purification of proteins: Proteins are purified by a mixed-mode chromatography system formed by attaching a ligand with cation exchange and hydrophobic functionalities to a large-pore support matrix, the only linkage between the ligand and the support matrix being a chain having a backbone of no more than three atoms between the hydrophobic group... Agent: Bio-rad Laboratories, Inc.

20130102762 - Anti-psgl-1 antibodies: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.... Agent:

20130102763 - Method of thermostabilization of a protein and/or stabilization towards organic solvents: Thermostabilization of a protein where the protein contains access routes and wherein at least one amino acid in the bottleneck of the access route is mutated, includes identifying the amino acids of the bottleneck and the amino acids control exchange of the solvent between a buried protein core and surrounding... Agent:

20130096275 - Vancomycin b hydrochloride crystalline form 1: Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed.... Agent: Abbott Laboratories

20130096276 - Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand: An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the acidic condition compared with known engineered Protein A ligands. The present invention provides a protein having an affinity for an immunoglobulin, including an amino acid sequence obtained by... Agent: Kaneka Corporation

20130096277 - Processes and intermediates:

20130096278 - Thiosulfonate compound, reversible cationization agent for protein and/or peptide, and method for solubilization:

20130096279 - Process for the purification of a growth factor protein:

20130096280 - Methods and composition for secretion of heterologous polypeptides: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof.... Agent: Genentech, Inc.

20130096281 - Methods and compositions for displaying a polypeptide on a yeast cell surface: Provided herein are methods and compositions for use in displaying a polypeptide (e.g., an antibody polypeptide or an antibody polypeptide fragment) on the surface of a yeast cell. Exemplary yeast that can be used in conjunction with various methods and compositions disclosed herein include those of the genus Yarrowia, e.g.,... Agent: Oxyrane Uk Limited

20130096282 - Therapeutic antibodies against flagellated pseudomonas aeruginosa: Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa, and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa, and said antibodies... Agent: Lostam Biopharmaceuticals Ltd

20130096283 - Method of supplementing culture media to prevent undesirable amino acid substitutions: The present invention relates to methods of reducing substitution of amino acids during the production of polypeptides of interest in mammalian cells. By varying the concentration of amino acids in the culture medium, heterogeneity of the polypeptide's amino acid sequence is decreased, leading to higher yields of functional protein.... Agent: Biogen Idec Ma Inc.

20130096284 - Method for purifying protein using amino acid: In large-scale purification of proteins such as antibodies, an economic high-purity purification method is required. The present invention relates to a method for purifying a protein, including one or more chromatographic processes, in which an amino acid; or a dipeptide, an oligopeptide, or a polyamino acid thereof is included in... Agent: Kyowa Hakko Kirin Co., Ltd.

20130096285 - Highly efficient lignin-based water-reducing agent with high degree of sulfonation and high molecular weight, and preparation method thereof: This invention discloses a high-performance lignin-based water reducer with high degree of sulfonation and high molecular weight and its preparation method. This water reducer exhibits an excellent water-reducing performance, its water-reducing rate of this lignin-based water reducer reaches 25% at a dosage of 0.70 wt %, which is higher than... Agent: